INOVIO PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
INOVIO PHARMACEUTICALS, INC. (INO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$92.95 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-12.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-12
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $4.30M, a 745.32% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $4.31M.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$22.42M, a 2442.13% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $13.72M, a 264.30% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$92.95K, a 102.00% decline from fiscal 2017.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $4.65M.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$38.50M, a 325.27% decline from fiscal 2015.
- INOVIO PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $17.09M, a 150.41% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $8.61M derived: sum of 2 quarters · filed 2019-03-12 | -$13.82M derived: sum of 3 quarters · filed 2019-03-12 | -$92.95K 10-K · filed 2019-03-12 |
| 2018-09-30 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$18.11M derived: sum of 2 quarters · filed 2018-11-08 | -$4.39M 10-Q · filed 2018-11-08 | -$3.88M derived: sum of 4 quarters · filed 2019-03-12 |
| 2018-06-30 | -$22.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$8.70M 10-Q · filed 2018-08-07 | -$8.19M derived: sum of 3 quarters · filed 2019-03-12 | -$8.77M derived: sum of 4 quarters · filed 2019-03-12 |
| 2018-03-31 | $13.72M 10-Q · filed 2018-05-09 | $14.23M derived: sum of 2 quarters · filed 2019-03-12 | $13.65M derived: sum of 3 quarters · filed 2019-03-12 | $14.61M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-12-31 | $508.19K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$74.06K derived: sum of 2 quarters · filed 2019-03-12 | $883.33K derived: sum of 3 quarters · filed 2019-03-12 | $4.65M 10-K · filed 2019-03-12 |
| 2017-09-30 | -$582.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $375.14K derived: sum of 2 quarters · filed 2018-11-08 | $4.14M 10-Q · filed 2018-11-08 | $27.63K derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $957.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $4.72M 10-Q · filed 2018-08-07 | $609.88K derived: sum of 3 quarters · filed 2019-03-12 | -$4.59M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $3.77M 10-Q · filed 2018-05-09 | -$347.51K derived: sum of 2 quarters · filed 2019-03-12 | -$5.55M derived: sum of 3 quarters · filed 2019-03-12 | -$18.72M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$4.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$9.31M derived: sum of 2 quarters · filed 2019-03-12 | -$22.49M derived: sum of 3 quarters · filed 2019-03-12 | -$38.50M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$18.37M derived: sum of 2 quarters · filed 2017-11-08 | -$34.38M 10-Q · filed 2017-11-08 | -$62.22M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | -$13.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$29.18M 10-Q · filed 2017-08-08 | -$57.02M derived: sum of 3 quarters · filed 2018-03-14 | -$41.85M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | -$16.01M 10-Q · filed 2017-05-10 | -$43.84M derived: sum of 2 quarters · filed 2018-03-14 | -$28.67M derived: sum of 3 quarters · filed 2018-03-14 | $15.48M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$27.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$12.66M derived: sum of 2 quarters · filed 2018-03-14 | $31.49M derived: sum of 3 quarters · filed 2018-03-14 | $17.09M 10-K · filed 2018-03-14 |
| 2015-09-30 | $15.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $59.32M derived: sum of 2 quarters · filed 2016-11-09 | $44.92M 10-Q · filed 2016-11-09 | $14.80M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $44.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $29.75M 10-Q · filed 2016-08-08 | -$371.43K derived: sum of 3 quarters · filed 2017-03-15 | -$18.24M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$14.40M 10-Q · filed 2016-05-09 | -$44.52M derived: sum of 2 quarters · filed 2017-03-15 | -$62.39M derived: sum of 3 quarters · filed 2017-03-15 | -$72.63M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | -$30.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$47.99M derived: sum of 2 quarters · filed 2017-03-15 | -$58.23M derived: sum of 3 quarters · filed 2017-03-15 | $6.82M 10-K · filed 2017-03-15 |
| 2014-09-30 | -$17.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$28.10M derived: sum of 2 quarters · filed 2015-11-09 | $36.95M 10-Q · filed 2015-11-09 | $37.60M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | -$10.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $54.82M 10-Q · filed 2015-08-10 | $55.47M derived: sum of 3 quarters · filed 2016-03-14 | $78.18M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $65.05M 10-Q · filed 2015-05-11 | $65.70M derived: sum of 2 quarters · filed 2016-03-14 | $88.42M derived: sum of 3 quarters · filed 2016-03-14 | $78.68M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $652.38K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $23.37M derived: sum of 2 quarters · filed 2016-03-14 | $13.63M derived: sum of 3 quarters · filed 2016-03-14 | $28.07M 10-K · filed 2016-03-14 |
| 2013-09-30 | $22.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $12.98M derived: sum of 2 quarters · filed 2014-11-10 | $27.42M 10-Q · filed 2014-11-10 | $28.48M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | -$9.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $4.71M 10-Q · filed 2014-08-11 | $5.76M derived: sum of 3 quarters · filed 2015-03-16 | $4.40M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $14.44M 10-Q · filed 2014-05-12 | $15.50M derived: sum of 2 quarters · filed 2015-03-16 | $14.13M derived: sum of 3 quarters · filed 2015-03-16 | $8.96M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$306.12K derived: sum of 2 quarters · filed 2015-03-16 | -$5.48M derived: sum of 3 quarters · filed 2015-03-16 | -$11.70M 10-K · filed 2015-03-16 |
| 2012-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$6.54M derived: sum of 2 quarters · filed 2013-11-12 | -$12.76M 10-Q · filed 2013-11-12 | -$20.71M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | -$5.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$11.40M 10-Q · filed 2013-08-09 | -$19.35M derived: sum of 3 quarters · filed 2014-03-17 | -$24.64M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | -$6.22M 10-Q · filed 2013-05-10 | -$14.17M derived: sum of 2 quarters · filed 2014-03-17 | -$19.47M derived: sum of 3 quarters · filed 2014-03-17 | -$26.05M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | -$7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$13.24M derived: sum of 2 quarters · filed 2014-03-17 | -$19.83M derived: sum of 3 quarters · filed 2014-03-17 | -$2.65M 10-K · filed 2014-03-17 |
| 2011-09-30 | -$5.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$11.88M derived: sum of 2 quarters · filed 2012-11-07 | $5.30M 10-Q · filed 2012-11-07 | $5.91M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | -$6.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $10.60M 10-Q · filed 2012-08-09 | $11.20M derived: sum of 3 quarters · filed 2013-03-18 | $15.64M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $17.18M 10-Q · filed 2012-05-09 | $17.79M derived: sum of 2 quarters · filed 2013-03-18 | $22.23M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $606.63K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $5.05M derived: sum of 2 quarters · filed 2013-03-18 | -$10.30M 10-K · filed 2013-03-18 | |
| 2010-09-30 | $4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$10.90M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$15.34M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $16.18M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |